Onassis Cardiac Surgery Center
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Onassis Cardiac Surgery Center advances research in cardiovascular diseases, targeting conditions such as heart failure, hypertrophic cardiomyopathy, and left ventricular systolic dysfunction. Clinical studies test the safety and therapeutic benefit of innovative drugs, including myosin inhibitors and mineralocorticoid receptor antagonists, aiming to enhance cardiac performance and patient well‑being.
- Hypertrophic cardiomyopathy (obstructive and non‑obstructive)
- Heart failure with reduced ejection fraction
- Novel myosin‑modulating agents
- Mineralocorticoid receptor antagonist therapy
- Cardiac imaging and functional outcome measures
Long‑term extension phases focus on tolerability, exercise capacity, and imaging biomarkers to confirm durable benefits.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Research at the Cardiology Department includes pediatric investigations of inherited cardiac disorders and early‑life heart failure. Trials evaluate agents such as finerenone in children with left ventricular systolic dysfunction, seeking safe, effective options for young patients with congenital or hereditary cardiomyopathies.
- Pediatric heart failure and left ventricular dysfunction
- Genetic cardiomyopathies
- Safety and dosing of novel therapies in children
- Impact on growth and developmental outcomes
- Biomarker‑driven efficacy assessments
The studies emphasize long‑term safety, quality of life, and the potential to expand treatment choices for children with complex cardiac conditions.
Respiratory Tract Diseases
The site’s portfolio also covers respiratory tract diseases, primarily focusing on pulmonary arterial hypertension (PAH) and PAH linked to interstitial lung disease. Clinical programs assess inhaled and injectable therapies—such as ralinepag, seralutinib, sotatercept, and PF‑07868489—to improve hemodynamics, exercise tolerance, and disease progression.
- Pulmonary arterial hypertension (PAH)
- PAH associated with interstitial lung disease
- Inhaled and systemic targeted agents
- Hemodynamic endpoints (e.g., PVR, 6‑minute walk distance)
- Patient‑reported outcomes and quality of life
Extended follow‑up studies monitor long‑term tolerability and the durability of clinical benefit in adult participants.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onassis Cardiac Surgery Center
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Finerenone | 3 | Unknown | 2025-09-01 | 2026-04-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.